Last updated: February 20, 2026
What is the drug associated with NDC 69452-0158?
NDC 69452-0158 corresponds to Erdafitinib (Balversa), a targeted therapy approved for adult patients with locally advanced or metastatic bladder cancer characterized by specific FGFR genetic alterations.
Market Size and Demand
Indication and Patient Population
- Indication: Treatment of FGFR2/3-mutated locally advanced or metastatic urothelial carcinoma.
- Prevalence: Urothelial carcinoma affects approximately 81,400 new cases annually in the U.S. (Per the American Cancer Society, 2022).
- FGFR Mutations: Present in about 15-20% of bladder cancers; estimated eligible population in the U.S. approximates 12,000-16,000 patients annually.
Competitive Landscape
- Existing Therapies: Chemotherapy, immunotherapy (e.g., pembrolizumab, atezolizumab).
- FGFR Inhibitors: Erdafitinib is the first FDA-approved FGFR inhibitor for this indication.
- Market Penetration: Initial uptake remains limited; projections depend on clinician awareness, diagnostic testing rate, and reimbursement.
Market Growth Drivers
- Increasing utilization of FGFR testing.
- Expansion of indications to earlier lines of therapy.
- Adoption in other FGFR-driven cancers, such as cholangiocarcinoma.
Pricing and Reimbursement
Current Price Point
- List Price: Approximately $16,000 - $17,000 per month for Erdafitinib, based on initial wholesale acquisition cost (WAC) reports (CMS reports, 2022).
- Annual Cost: Roughly $192,000 - $204,000 for a standard year of treatment.
Cost components
- Drug acquisition cost dominates.
- Reimbursement varies due to insurance coverage, Medicare pricing, and negotiated discounts.
- Patient assistance programs can reduce out-of-pocket expenses.
Factors Affecting Price
- Reimbursement negotiations.
- Patent lifecycle and potential biosimilar entries pending patent expiry or legal challenges.
- Development of companion diagnostics may influence cost structures and reimbursement policies.
Price Projections for the Next 3-5 Years
Factors Influencing Price Trends
- Market Competition: Entry of new FGFR inhibitors or generics.
- Regulatory Changes: Biosimilar or generic approvals could drive prices downward.
- Healthcare Policy: Value-based pricing models and formulary negotiations.
Projections
| Year |
Estimated Average Monthly Price |
Notes |
| 2023 |
$16,000 |
Current list price |
| 2024 |
$15,500 - $16,000 |
Slight decrease expected due to competitive pressure |
| 2025 |
$14,500 - $15,500 |
Potential entry of biosimilars or generics |
| 2026 |
$13,500 - $15,000 |
Further price reduction with market maturation |
| 2027 |
$12,000 - $14,000 |
Likely stabilized, assuming patent exclusivity |
Note: These are approximations based on current trends, industry analyst reports, and market dynamics[1].
Regulatory and Policy Impact
- The FDA's push toward personalized medicine emphasizes diagnostic testing, which can influence market size and pricing strategies.
- Payers are increasingly favoring value-based arrangements, potentially leading to discounts or outcomes-based pricing models.
- Patent protections expected to expire around 2028-2029, possibly inviting biosimilar competition.
Summary of Key Data Points
| Aspect |
Data |
| Target Patient Population (US) |
12,000–16,000 annually |
| Current List Price |
$16,000 - $17,000/month |
| Annual Cost |
~$192,000 - $204,000 |
| Market Growth Drivers |
Increased FGFR testing, early-line expansion |
| Projected Price Trend (2023–2027) |
Decrease from $16,000 to ~$12,000 per month |
Key Takeaways
- Erdafitinib targets a niche but growing segment within bladder cancer treatment.
- The drug's high list price faces pressure from biosimilar competition and value-based pricing models.
- Growth in market share depends on diagnostic testing adoption and clinical guideline integration.
- Long-term price stabilization may occur post-patent expiry in the late 2020s.
FAQs
1. How does Erdafitinib compare to other FGFR inhibitors?
Erdafitinib was the first FDA-approved FGFR inhibitor for bladder cancer. Its main competitor is infigratinib, with similar indications but different pricing and approval status.
2. What factors influence reimbursement rates for Erdafitinib?
Coverage depends on insurance policies, the availability of diagnostic testing, clinical guideline endorsement, and outcome data supporting value.
3. Will biosimilars significantly reduce Erdafitinib prices?
Patent expiry around 2028-2029 could lead to biosimilar entries, potentially reducing prices by 20-40%.
4. How important is FGFR testing for market penetration?
Critical; accurate testing determines eligibility, directly impacting sales volume.
5. Are there ongoing clinical trials expanding Erdafitinib’s indications?
Yes, research continues into early-line settings and other FGFR-driven cancers, which could expand market opportunities.
References
[1] IQVIA. (2022). Market Dynamics of Oncology Drugs. IQVIA Report.
[2] American Cancer Society. (2022). Cancer Statistics.
[3] U.S. Food and Drug Administration. (2019). Erdafitinib (Balversa) prescribing information.
